Obesity drug AZD4144 shows early safety signals in small trial
NCT ID NCT06942923
First seen Nov 01, 2025 · Last updated Jun 15, 2026 · Updated 32 times
Summary
This early-stage study tested a daily pill called AZD4144 in 28 people with obesity to see if it is safe and how it affects inflammation in the body. Participants took either the drug or a placebo for a short time. The main goals were to check for side effects and measure changes in blood markers like interleukin-6 (IL-6), which is linked to inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Berlin, 14050, Germany
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.